Quanterix Corporation
QTRX Healthcare Medical Devices
Quanterix Corporation’s revenue for fiscal 2025 (year ended December 2025) was $138.9 million, up 1.07% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS fell 35.1% and free cash flow grew 18.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow QTRX
Quanterix Corporation (QTRX) EV/Sales
As of 16 October 2026, Quanterix Corporation (QTRX) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from −0.4× (May 2025) to 29.3× (February 2021); the current reading is higher than 10% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.1× | (3.29%) |
| FY2024 | 1.2× | (80.86%) |
| FY2023 | 6.0× | 253.60% |
| FY2022 | 1.7× | (83.60%) |
| FY2021 | 10.4× | (26.44%) |
| FY2020 | 14.2× | 63.58% |
| FY2019 | 8.7× | (12.73%) |
| FY2018 | 9.9× | 180.77% |
| FY2017 | 3.5× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | 55.32% |
| Mar 2026 | 0.5× | (57.72%) |
| Dec 2025 | 1.1× | 23.71% |
| Sep 2025 | 0.9× | 201.33% |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RXST RxSight, Inc. compare | 0.0× |
| INGN Inogen, Inc compare | 0.2× |
| QTRX Quanterix Corporation | 0.3× |
| OWLT Owlet, Inc. compare | 0.9× |
| ZOMDF Zomedica Corp. compare | 0.9× |
| STIM Neuronetics, Inc. compare | 1.2× |
| MXCT MaxCyte, Inc. compare | 1.2× |
| APYX Apyx Medical Corporation compare | 2.2× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)